Introduction
The ezrin-radixin-moesin family molecule, merlin, is the protein product of the neurofibromatosis type 2 (NF2) tumor suppressor gene, which is inactivated in familial NF2 and in other types of sporadic tumors, including schwannomas, mesotheliomas and meningiomas. The NF2 tumor suppressor gene is unique in that it exerts its tumor-suppressive functions from the cell-environment interface rather than from within the cell to impact cell proliferation (McClatchey and Giovannini, 2005) .
A hallmark of NF2-deficient cells is the loss of contact inhibition of proliferation (Morrison et al., 2001; Johnson et al., 2002; Lallemand et al., 2003) . Several studies have proposed that the lack of association of merlin with Rac1 GTPase, CD44 or paxillin might be responsible for the destabilization of cell-cell contacts that allow for the loss of contact inhibition in NF2-deficient cells (Morrison et al., 2001; Fernandez-Valle et al., 2002; Okada et al., 2005) . A recent study has provided the first mechanistic insight by attributing this characteristic of NF2-deficient cells to their inability to silence epidermal growth factor receptor (EGFR) signaling at confluency (Curto et al., 2007) . Despite these observations, our understanding of the mechanisms through which the loss of the cell membrane-associated protein, merlin, transduces the growth signal to the nucleus that is necessary for cell proliferation at confluency remains rudimentary.
Rac1, a member of the Rho GTPase family of signal transducers, is a pleiotropic regulator of multiple signaling pathways, including mitogen-activated protein kinase (MAPK), JNK/SAPK (c-Jun N-terminal kinase/stress-activated protein kinase), nuclear factor-kB and PI-3K (phosphoinositide-3 kinase), allowing it to regulate a diverse set of cellular processes. Rac1 is a modifier of tumorigenesis and its overexpression or overactivation occurs in many tumor types (Fritz et al., 1999; Jordan et al., 1999) . Studies have shown that Rac1 signaling is critical in both tumor formation and progression because of its involvement in cell migration, cell-cycle progression and Ras-induced foci formation (Sahai and Marshall, 2002) . As the Wnt signal transduction pathway has been established as a critical modifier of tumorigenesis, several studies have focused on linking Rac1 activity to Wnt signaling. Until recently, it was believed that Rac1 may affect noncanonical, or b-catenin independent, Wnt signaling (Malliri and Collard, 2003) and is involved in canonical Wnt signaling only in cells containing stabilized pools of b-catenin (Esufali and Bapat, 2004) . However, a recent study in osteoblast development indicates that Rac1 is critical for the nuclear translocation of b-catenin and subsequent activation of T-cell factor 4 (TCF4) (Upadhyay et al., 2008; Wu et al., 2008) . Yet, whether the physiologically relevant association of Rac1 with canonical Wnt signaling in osteoblasts is applicable to potential pathological context has not been investigated.
Although the functional relationship between merlin, Rac1 and its downstream effector PAK has been extensively studied, the contribution of Rac1 signaling to the loss of contact inhibition in NF2-deficient cells has not been demonstrated. It has been shown that levels of active Rac1 are increased in NF2-deficient cells (Kaempchen et al., 2003; Nakai et al., 2006; Ammoun et al., 2008) . Furthermore, merlin knockdown promotes the recruitment of Rac1 to matrix adhesions, which correlates with release of cells from contact inhibition (Okada et al., 2005) . Together, these studies suggest a mechanism by which Rac1 could modulate signaling to the nucleus in the context of NF2 deficiency.
In this study, we provide the first evidence that Rac1-mediated canonical Wnt signaling contributes to the loss of contact inhibition in NF2-deficient cells. We specifically show that Rac1 is required for canonical Wnt signaling in the pathological context of NF2 tumorsuppressor loss. In addition, we found that loss of NF2 increases the transcriptional activity of the nuclear pool of b-catenin in a Rac-dependent manner. One downstream consequence of this is the increased amount and transcriptional activation of cell cycle-promoting factors, c-myc and cyclin D1, which may be the mechanism by which NF2-deficient cells transduce signals from the cell membrane to the nucleus in order to achieve loss of contact inhibition. Our studies show that Rac1-mediated canonical Wnt signaling is critical for the loss of contact inhibition phenotype of NF2-deficient cells and that the Rac1-Wnt signaling axis could serve as a new node of therapy for NF2-associated disease.
Results
The phenotypes of NF2 loss in primary cells are maintained in immortalized NF2-deficient MEFs In the literature, many seminal studies that define the role of merlin in maintaining cellular contacts have been conducted in primary mouse embryonic fibroblasts (MEFs). These studies have been the cornerstone of our understanding of the tumor suppressor, merlin. In this study, primary NF2 flox2/flox2 MEFs were infected with an adenovirus encoding Cre recombinase (Ad-GFP Cre) or a control adenovirus (Ad-GFP), and the cells were harvested for genomic PCR of the NF2 gene to validate functional deletion 96 h after infection. Concurrently, spontaneously immortalized clones were derived from these two cell types. The genomic deletion of NF2 in immortalized cells was confirmed by the smaller size of the PCR product on infection with Cre recombinase (442 bp as compared with 338 bp) and was comparable with the deletion evident in primary lines ( Figure 1a , left panel). By immunoblotting for merlin, we show an efficient loss of the merlin protein after infection in the immortalized cells ( Figure 1a , right panel). To ensure that our immortalized cell model has maintained the published phentoypes of NF2 deficiency in primary MEFs, both contact inhibition and adherens junction stability were examined. NF2 deficiency indeed conferred loss of contact inhibition of proliferation in the immortalized cells as shown by growth assay (Figure 1b) . Similarly, at confluency, destabilization of adherens junctions in immortalized NF2À/À cells was (Figure 1c) . These phenotypes are similar to what was reported in primary cell cultures in the study by Lallemand et al. (2003) . Although the localization of b-catenin to adherens junctions is disrupted in NF2-deficient cells upon confluency, the total amount of cellular b-catenin remains similar in both cell types as assessed by immunoblot (Figure 1d ). These data are also in agreement with previous findings by Curto et al. (2007) that NF2 deficiency results in a loss of contact inhibition and reduced adherens junction, and thus validate our immortalized cell model.
NF2 deficiency increases canonical Wnt signaling
Next, we sought to understand whether NF2-deficient cells could have an increase in nuclear b-catenin activity as the junctional levels are reduced, yet the total levels remain similar to those of wild-type cells. Nuclear bcatenin has a relatively fast turnover that is difficult to detect and we, similar to Curto et al. (2007) , did not identify significant differences in protein levels of the nuclear fraction of b-catenin by western blotting (data not shown). Therefore, we instead measured the transactivation of the TCF4 transcription factor by reporter assay, as it is directly responsive to nuclear b-catenin. In both primary (Figure 2 , left panel) and immortalized cells (Figure 2 , right panel), we observed a four-to six-fold increase in TCF4 transcription factor activity (TOPflash) when NF2 was excised, whereas the TCF-mut showed minimal activation in all samples (FOPflash). As hyperactive Wnt signaling and the loss of contact inhibition phenomena are shared between primary and immortalized cells, all subsequent experiments are carried out with the immortalized cell line.
Rac1 is necessary for the elevated Wnt activity in NF2À/À cells To probe the signaling events that contribute to Wnt pathway hyperactivation in the absence of merlin, both NF2-proficient and NF2-deficient cells were harvested for immunoblot. Similar to what has been shown in Schwann cells (Kaempchen et al., 2003; Nakai et al., 2006; Ammoun et al., 2008) , active Rac1 signaling was increased in NF2-deficient cells as two downstream effectors of Rac1, PAK and Akt, became hyperactivated ( Figure 3a) . Previous studies by the Clevers laboratory showed that active b-catenin, or the fraction that is dephosphorylated on ser37 and Thr 41, is indicative of the transcriptionally active portion of b-catenin in the cell (van Noort et al., 2002) . In addition, recent reports have shown that phospho-b-catenin Y142 is a phosphorylation event which marks the dissociation of b-catenin from adherens junctions, leading to a switch toward its nuclear accumulation (Aberle et al., 1996; Brembeck et al., 2004; Sampietro et al., 2006) . In the absence of merlin, we found that the levels of nuclear b-catenin, as determined by both 'active' or NH 2 terminally dephosphorylated b-catenin and phospho-bcatenin Y142, were elevated as compared with total b-catenin levels. Concomitantly, increased levels of one of the TCF4 transcription factor targets, cyclin D1, was evident in NF2-deficient cells, further confirming the elevated canonical Wnt signaling in these cells ( Figure 3a ). To verify that the heightened level of cyclin D1 protein in the absence of merlin was Rac1 promotes loss of contact inhibition EE Bosco et al transcriptionally active, we performed a reporter assay with NF2-proficient and NF2-deficient cells transfected with the cyclin D1-luc reporter. NF2À/À cells showed a 3.5-fold increase in cyclin D1 transcriptional activity as compared with control cells (Figure 3b ). Together, these results indicate that Rac1 and canonical Wnt signaling are significantly increased in the absence of merlin.
To dissect the functional relationship between Rac1 and the canonical Wnt pathway, Rac1 activity was inhibited by using the dominant-negative Rac1 mutant, (Rac1 N17), the Rac1-specific small molecule inhibitor (NSC23766), or lentiviral shRNA to Rac1, matched with a scrambled control (shSCR). A TCF4-luciferase reporter assay was performed in wild-type cells that had been transduced with a retrovirus encoding either the MIEG3-Rac1 N17 mutant or the control MIEG3 alone. This was also executed in cells transduced with lentivirus expressing YFP-tagged shRac1 or shSCR. Cells were sorted by flow cytometry for GFP expression (encoded by MIEG3 virus) or YFP expression (encoded by sh lentivirus) before transfection with the reporter constructs, and a subset were treated with 100 mM NSC23766 24 h before harvest and/or 100 ng/ml Wnt3a 8 h before harvest. As expected, treatment of control MIEG3-infected cells with Wnt3a significantly induced TCF4 reporter activity more than eightfold over untreated cells (results were nearly identical with shSCR controls and are not shown). This induction of TCF4 transactivation was abrogated by pharmacological, shRNA and dominant-negative Rac1 inhibition (Figure 4a , left panel). Wild-type cells transduced with lentivirus encoding YFP-tagged shSCR or shRac1 were sorted on the basis of YFP expression and immunoblotted to validate the Rac1 gene knockdown before use in the aforementioned luciferase reporters (Figure 4a , right panel). The results of these reporter assays are in agreement with a recent study in the osteoblast model (Wu et al., 2008) , indicating that Rac1 activity is a critical component of the canonical Wnt signaling pathway.
To understand the contribution of Rac1 to the regulation of the canonical Wnt pathway in a pathological context, similar experiments were conducted in Ad-GFP or Ad-GFP Cre-infected NF2 flox2/flox2 immortalized MEFs. Wnt3a stimulation resulted in heightened TCF4 transactivation, and this effect was increased in the absence of NF2. However, TCF4 transactivation was completely blocked in NF2À/À cells by Rac1 targeting either through the use of the dominant-negative Rac1 mutant, MIEG3-Rac1 N17, or shRac1. This inhibitory effect of Rac1 targeting on TCF4 transactivation was also evident on Wnt3a-stimulated wild-type cells (Figure 4b ). This result indicates that Rac1 is necessary for the elevation of canonical Wnt pathway signaling in the absence of merlin.
The c-myc and cyclin D1 genes are well-characterized downstream targets of the Wnt pathway. To verify the enhancing effect of Rac1 on Wnt signaling in NF2-deficient cells, we performed quantitative PCR to determine the relative abundance of both genes with respect to a GAPDH (glyceraldehyde 3 phosphate dehydrogenase) control. Ad-GFP or Ad-GFP Creinfected cells were transduced with MIEG3-Rac1 N17 or MIEG3 alone and sorted on the basis of GFP expression. Cells were then plated at confluency to determine the impact of Rac1 blockade on the induction of c-myc and cyclin D1, which are important for cell proliferation and therefore could exhibit inappropriately high levels upon loss of contact inhibition. As shown in Figure 4c , the levels of both genes are elevated in control-infected NF2À/À cells, and dominant-negative inhibition of Rac1 was able to reduce the expression of both genes to levels comparable with those in NF2-proficient cells. These data indicate that Rac1 contributes to the increase in c-myc and cyclin D1 in NF2À/À cells under confluent conditions.
Wnt signaling contributes to the loss of contact inhibition in NF2-deficient MEFs
We next sought to determine the effect of increased b-catenin activity on the loss of contact inhibition of proliferation of NF2-deficient cells by using a dominant-negative mutant of TCF4 (dnTCF4). dnTCF4 is an N-terminal deletion of TCF4 that is unable to bind b-catenin, yet retains the ability to bind to DNA, and is thus effective in blocking transcriptionally active b-catenin from binding DNA (Tetsu and McCormick, 1999) . First, we either transfected Ad-GFP or Ad-GFP Cre-infected cells with pSFG-control DNA or pSFGdnTCF4 and sorted the cells by flow cytometry, before performing a TCF4 reporter assay. dnTCF4 was found to efficiently block TCF4 transactivation in response to Wnt3a stimulation and restored the level of TCF4 hyperactivation in NF2À/À cells to levels comparable with those in wild-type cells (Figure 5a ), indicating that Wnt pathway inhibition was functional. Second, we tested whether dnTCF4 was able to inhibit the elevated TCF4 activity in NF2À/À cells at confluency. As shown in Figure 5b , upon dnTCF4 expression, the TCF4 transcriptional activity in confluent NF2-deficient cells was attenuated B10-fold. These results suggest that the loss of contact inhibition in NF2-deficient cells at confluency is associated with Wnt pathway hyperactivation. Third, we examined the cell-proliferative activity in the confluent state using a 5-bromo-2-deoxyuridine (BrdU) incorporation assay. Not surprisingly, the number of Ad-GFP infected cells that were able to enter S phase was greatly reduced as compared with the Ad-GFP Cre-infected controls at confluency, and dnTCF4 did not significantly effect the ability of the Ad-GFP-infected cells to enter S phase. In contrast, the Ad-GFP Cre-infected cells exhibited B60% decrease in proliferative capacity after dnTCF4 transfection (Figure 5c ). The results of these Wnt signaling inhibition experiments indicate that merlin-deficient cells depend on Wnt/TCF4 signaling to achieve the loss of contact inhibition. To directly test the requirement of active Rac1 for loss of contact inhibition in merlin-deficient cells, Ad-GFP or Ad-GFP Cre-infected cells were transduced with a virus encoding either MIEG3 alone or MIEG3-Rac1 N17. Similar to Figure 5c , BrdU/PI analysis showed that Ad-GFP-infected cells are contact inhibited and that their cell-cycle progression was thus unaffected by dominant-negative Rac1 (Figure 5d ). However, Ad-GFP Cre-infected cells exhibited a twofold increase in BrdU incorporation at confluency, which was abrogated by the addition of Rac1 N17, indicating that Rac1 activity significantly contributes to loss of contact inhibition in NF2À/À cells. When dnTCF4 and Rac1 N17 were cointroduced into NF2À/À cells, a similar degree of inhibition of BrdU incorporation at confluency was evident as compared with dnTCF4 or Rac1 N17 expression alone (data not shown). These data further suggest that Rac1 and bcatenin signal in the same pathway to impact the loss of contact inhibition in NF2À/À cells.
Small molecule inhibition of Wnt signaling suppresses the loss of contact inhibition of NF2-deficient cells To demonstrate the therapeutic relevance of the proposed dependence of NF2-deficient cells on the Rac-mediated Wnt pathway in order to achieve loss of 
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EE Bosco et al contact inhibition, a natural small molecule inhibitor of the Wnt pathway, PKF115-584 (Lepourcelet et al., 2004) was used. Similar to the dnTCF4 mutant, the PKF115-584 small molecule prevents the formation of the b-catenin-TCF4 complex, thereby inhibiting its ability to bind DNA (Lepourcelet et al., 2004) . Treatment of MEF cells in our study with 10 mM PKF115-584 for 18 h was able to abrogate the expression of the bcatenin downstream target, cyclin D1, with minimal toxicity, and thus is the dose we proceeded with in further experiments. Consistent with what has been observed in acute myeloid leukemia cell lines (Minke et al., 2009 ), inhibition of b-catenin expression itself was also evident after treatment with the Wnt inhibitor ( Figure 6a , right panel). To determine the effectiveness of PKF115-584 on TCF4 transactivation, Ad-GFP and Ad-GFP Cre-infected NF2 floxed MEFs were treated with dimethyl sulfoxide control or 10 mM PKF115-584 for 18 h in combination with Wnt3a stimulation in the final 8 h before harvesting for TCF4 reporter assay. PKF115-584 significantly inhibited the activation of TCF4 in response to Wnt3a, independent of the activity of NF2 (Figure 6a , left panel). To specifically examine the ability of PKF115-584 to block Wnt signaling in NF2-deficient cells at confluency, Ad-GFP and Ad-GFP Cre-infected cells were seeded under confluent conditions and treated with PKF115-584 or vehicle control before the TCF4 reporter assay. The small molecule inhibitor was effective in blocking the hyperactivation of TCF4 in NF2-deficient cells at confluency, and showed minimal effect on the already reduced level of TCF4 transactivation in NF2-proficient cells (Figure 6b) . Finally, to verify that such Wnt pathway inhibition can affect cell-cycle progression at confluency, NF2-proficient and NF2-deficient cells cultured under confluent conditions were treated with vehicle control or PKF115-584 for 18 h, pulsed with BrdU for the final 1 h and harvested for BrdU fluorescence-activated cell sorter (FACS) analysis. As shown in Figure 6c , PKF115-584 completely blocked the ability of the Ad-GFP Cre-infected cells to proliferate at confluency. These results suggest that the dependence of NF2-deficient cells on Wnt signaling for the loss of contact inhibition could be useful in reversing this phenotype.
Discussion
Loss of contact inhibition of cell proliferation is the signature phenotype of cells lacking the tumor suppressor, merlin. Associated with loss of contact inhibition, merlin-deficient cells are known to contain defective adherens junctions at confluency with unstablized cadherin-catenin complexes (McClatchey and Giovan- cells, suggesting that merlin restrains EGFR activity at the cell membrane (Curto et al., 2007) . Our current study provides new evidence that the relationship of merlin with EGFR is not the only mechanism by which NF2À/À cells are able to escape contact inhibition. Data are represented as TCF4-luc/TCF4-mut-luc and normalized to the activity of the untreated DMSO vehicle control, Ad-GFPinfected cells (left panel). Ad-GFP Cre-infected MEFs were treated with 10 mM PKF115-584 for 18 h before harvest for immunoblot to verify inhibition of b-catenin and cyclin D1. Actin served as a loading control. (b) Cells from panel a were grown to confluency before harvest for luciferase reporter assay and normalized to the activity of the untreated DMSO vehicle control which was set to 1. (c) Upper panel: Ad-GFP or Ad-GFP Cre-infected MEFs were grown to confluency, treated with either DMSO vehicle or 10 mM PKF115-584, and pulsed with BrdU for 1 h before harvest for BrdU/PI analysis. Data are normalized to the Ad-GFP-infected, DMSO-treated control cells, which are set to 1. Lower panel: Representative histograms from FACS analysis are displayed.
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Similar to the observations made in the study by Curto et al. (2007) , we show that the total level of b-catenin is unaltered by the loss of merlin. However, in contrast to that study, we found a significant increase in transcriptionally active b-catenin upon merlin deletion. This is established by several means. First, we found that increased TCF/LEF transcription factor activity (Figure 2a) , which is a direct downstream target of activated b-catenin in the nucleus, exists in the absence of merlin. Second, NF2À/À cells contained an increase in both active b-catenin and phospho-b-catenin Y142 levels (Figure 3a) , which have been shown to be markers for b-catenin that is being translocated from the cell membrane to the nucleus. Third, elevations in mRNA (Figure 4c ) and transcriptional activity (Figure 3b ) of downstream targets of activated b-catenin were evident in the absence of merlin. Thus, we believe that deregulated canonical Wnt signaling is associated with NF2 loss of function. To examine whether the increased nuclear b-catenin activity could be a causal event in the ability of NF2À/À cells to inappropriately proliferate at confluency, we restored basal levels of TCF/LEF transcriptional activity to NF2À/À cells either through the use of a dominant-negative TCF4 construct or a small molecule Wnt pathway inhibitor, PFK115-584 (Figures 5b and 6b) . Suppressing either the elevated TCF or Rac1 activities in merlin-deficient cells significantly reduced the capacity of NF2-deficient cells to enter S phase at confluency (Figures 5c, d and 6c) . Collectively, our results show that the elevated nuclear b-catenin activity in NF2-deficient cells contributes to the growth phenotype of cells at the confluent state.
Similar to many classical tumor suppressors, the activity of merlin is governed by its phosphorylation state. Several seminal papers in the study of NF2 have linked merlin activity to its phosphorylation induced by Rac1-GTP and its downstream effector PAK (Shaw et al., 2001; Kissil et al., 2002; McClatchey and Giovannini, 2005) . The ser518 phosphorylation of merlin weakens its self-and cytoskeletal-associations, inactivates its growth-suppressive properties and potentiates Rac-dependent signaling (Gutmann et al., 1999; Kissil et al., 2002; Xiao et al., 2002) . This opposing relationship between Rac1 and merlin is strengthened by observations that overexpression of merlin inhibits the Rac1 signaling axis, specifically PAK1 and JNK, and downregulates cyclin D1 Xiao et al., 2002; Kaempchen et al., 2003) . Moreover, it is also established that NF2À/À cells contain very high levels of active Rac1 (Kaempchen et al., 2003; Nakai et al., 2006; Ammoun et al., 2008) . Thus, in light of the recent evidence that Rac1 is critical for canonical Wnt pathway signaling (Wu et al., 2008) , we examined the relationship between active Rac1 and elevated Wnt signaling in the context of NF2 deficiency-induced inappropriate proliferation. We first confirmed that Rac1 is necessary for canonical Wnt signaling in the NF2 loss-of-function context, a pathologically relevant model system (Figure 4a ), as previous experiments in osteoblasts and NIH 3T3 cells do not address such a relevance (Wu et al., 2008) . Next, we found that Rac1 activity was indeed responsible for the elevation in canonical Wnt signaling in NF2-deficient cells, as Rac1 inhibition with a dominant-negative mutant, small molecule inhibitor or shRNA eliminated TCF4 transcriptional activation (Figure 4b ), and transcription of downstream targets c-myc and cyclin D1 (Figure 4c ). Although our data do not define a mechanism through which Rac1-GTP can impact Wnt signaling in the context of merlin loss, it could be envisioned to occur through various Rac effectors, such as the MAPK, Akt or JNK (Chadee et al., 2006; Tang et al., 2007; Wu et al., 2008) . As the inhibitory effect of Rac1 N17 together with dnTCF4 on the confluent NF2À/À cell proliferation was comparable with that by Rac1 N17 or dnTCF4 alone ( Figure 5 ; data not shown), it is likely that Rac1 and TCF4 activities do not synergize and may act as a part of the same pathway containing NF2-Rac1-b-catenin-contact inhibition.
Recent advances in the study of NF2 have indicated that merlin is a tumor suppressor that is capable of modulating a wide range of signaling pathways that influence cell growth, motility and apoptosis. Similar to our results in MEFs, a recent study in high-grade human gliomas has also concluded that NF2 loss results in an increase in Wnt signaling, specifically TCF transcription factor activity (Lau et al., 2008) . This study found that merlin acts to increase expression of molecules that inhibit canonical Wnt signaling (Dkk-1 and Dkk-3) and decrease expression of molecules that activate Rac1/RhoA signaling (Vav3) (Lyons and Burnstein, 2006; Colomba et al., 2008) . Keeping the glioma model in mind, it is possible that elevated levels of active Rac1 in the absence of merlin are due to unrestrained Vav3 activity in NF2-associated tumors as well and could serve as another potential point of therapeutic intervention in the disease.
As schwannomas are benign and relatively slow growing, they do not respond well to traditional chemotherapy and often result in morbidity. Treatment strategies are centered on local tumor control by repeated surgeries and radiation, which can have detrimental effects on the nerves and are made more challenging by tumor location and multiplicity. Thus, new pharmacological treatment strategies are urgently required. As NF2 patients typically suffer from schwannomas and meningiomas, a further study is necessary in these disease models to apply our observations. In this context, our study provides new insight into the tumorsuppressive activity of merlin and suggests that targeting the Rac-Wnt pathway could serve as a novel therapeutic strategy for NF2-associated disease.
Materials and methods
Cell culture, viral infection and growth assays NF2 flox2/flox2 MEFs were a kind gift from Dr Marco Giovannini (House Ear Institute, Los Angeles, CA, USA). Clones of spontaneously immortalized MEFs were selected and used throughout the study. All cells were maintained in Dulbecco's modied Eagle's medium supplied with 10% fetal bovine serum, 2 mM L-glutamine and 100 Units/ml penicillin/streptomycin at 37 1C in air containing 5% CO 2 . In this study, all primary cells were between passages 3 and 5. NF2 deletion was achieved by infection with replication defective recombinant Ad-GFP or GFP in addition to Cre recombinase (Ad-GFP Cre). Adenovirus was used at B2 Â 10 7 virus particles per dish to achieve an infection efficiency of 90-95% as determined by GFP immunofluorescence. Cells were cultured for at least 4 days after adenoviral infection before use, whereas the passage number and length of time after infection remained consistent throughout all experiments unless otherwise stated. Infections of cells with retrovirus encoding MIEG3 or MIEG3-Rac1 N17 or lentivirus encoding shRNA to Rac1 or scrambled control (Sigma PLKO shGly plasmid, Sigma-Aldrich, St Louis, MO, USA) were performed according to standard protocol, and cells were sorted on the basis of GFP (MIEG3) or YFP (shRNA) expression 48 h after infection. Cell growth assays were performed by trypsinization and counting by trypan blue exclusion every 3 days. All assays were performed at subconfluency unless stated otherwise. For studies in the confluent condition, 4 Â 10 6 cells were seeded in a 10-cm tissue culture dish, whereas subconfluent studies were conducted with B5 Â 10 5 cells in the same size dish.
Genomic PCR analysis of recombination and quantitative PCR Genomic PCR analysis was performed to verify adenoviralCre-mediated recombination in primary and immortalized MEFs. Total genomic DNA was extracted using the Blood and Tissue DNA kit (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol and amplified using the PCR conditions and the following primers as previously described (Giovannini et al., 2000) :
RNA was extracted using the RNeasy mini kit (Qiagen), and cDNA was synthesized from 1 mg of RNA with the SuperScript RT-PCR system (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. cDNAs were amplified by quantitative PCR using TaqMan gene expression assays for cyclin D1, c-myc, and gapdh with TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol. Assays were run on an ABI Prism 7900 HT sequence detection system (Applied Biosystems).
Transfection, reporter assay and BrdU incorporation Cells were cotransfected with TCF4-luciferase (TOPflash), TCF4-mutant-luciferase (FOPflash) (Upstate Biotechnology, Lake Placid, NY, USA) or cyclin D1-luciferase (generously provided by Dr Karen Knudsen, Thomas Jefferson University, Philadelphia, PA, USA) reporter plasmids and a plasmid encoding b-galactosidase for normalization using FuGENE 6 Transfection Reagent (Roche, Nutley, NJ, USA). Forty-eight hours after transfection, reporter activity was measured using the Luciferase assay kit (Promega, Madison, WI, USA) following manufacturer's protocol. Wnt3A (R&D Systems, Minneapolis, MN, USA) stimulation for reporter assay was performed for 8 h before cell harvest and NSC23766 treatment lasted 24 h before harvest. All reporter assays were performed on nonconfluent cells unless otherwise stated and at least three times in triplicate. Untreated control cells were normalized to 1. Cells were transfected with pSFG or pSFG-dnTCF4 plasmids (a kind gift from Dr Fanxin Long, Washington University, St Louis, MO, USA) and subjected to TCF4 reporter assay as described above. For S-phase analysis, cells were transfected with MIEG3, MIEG3-Rac1 N17, pSFG or pSFG-dnTCF4 and H2B-GFP and sorted by flow cytometry on the basis of GFP expression and were then cultured for 24 h. Next, cells were labeled with BrdU (GE Healthcare, Little Chalfont Buckinghamshire, UK) for 1 h before fixation and staining for BrdU/PI FACS analysis as described previously (Bosco et al., 2004 ) using a FACSCanto flow cytometer and FACSDiva software (BD Biosciences, San Diego, CA, USA). PKF115-584 was kindly provided by Novartis (Basel, Switzerland) and used at 10 mM in cell culture for 18 h.
Immunoblotting and immunofluorescence
Whole-cell lysates were prepared by cell extraction using lysis buffer containing 20 mM Tris-HCl (pH 7.6), 100 mM NaCl, 10 mM MgCl 2 , 1% Triton X-100, 0.2% sodium deoxycholate, 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml of leupeptin, 1 mg/ml of aprotinin and 1 mM dithiothreitol for 30 min. Equal amounts of protein, as determined by Bradford assay, were resolved by SDS-PAGE. Specific proteins were detected by standard immunoblotting procedures using the following primary antibodies: (Thermo Fisher Scientific, Fremont, CA, USA, 1:500 dilution) Cyclin D1 Ab-3 (Cell Signaling, Danvers, MA, USA, 1:500 dilution) phospho-PAK1 (Thr 423)/PAK2 (Thr 402), phospho-Akt (S473), merlin (9168), (BD Biosciences 1:500 dilution) Rac1, b-catenin (610 153), (Millipore, Billerica, MA, USA, 1:500) active b-catenin (05-665), (Abcam Inc., Cambridge, MA, USA, 1:500) phospho-b-catenin Y142 (27798-50), (Sigma-Aldrich 1:500) actin. Wnt3A (R&D Systems) stimulation for immunoblot was performed for 1 h before cell harvest. For immunofluorescence, cells were cultured on coverslips before fixation with 3.7% formaldehyde (Sigma-Aldrich). Cells were permeabilized using 0.5% Triton X-100 (Sigma-Aldrich) and stained for immunofluorescence using the previously mentioned antibody for b-catenin and 4 0 ,6-diamidino-2-phenylindole (Invitrogen).
